Pluristem Therapeutics - PLUR Quarterly EPS earnings growth

Pluri Inc. - graphic logo of issuer PLUR

Pluri Inc. (PLUR) quarterly earnings per share growth demonstrates the impact of CDMO services commercialization and successes in the cultivated meat sector. This trend is supported by the implementation of AI robots in 3D bioreactors to eliminate defects, with -30.60 representing the current metric. Leading biochemists working on placental therapy patent platforms under long-term incentive programs ensure price stability.

Pluri (PLUR) - Year-over-year earnings per share growth for the last twelve months from 04/28/2023 to 11/14/2026

Financial and market metric breakdowns for pluri-biotech.com (PLUR)

- share price and consensus valuation forecast:
Stock Quotes pluri-biotech.com|PLUR - Analyst Forecast Prices
- issuer market value details:
Market Capitalization PLUR|PLUR - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Pluri|PLUR - Company Book Value|Market Value to Book Value Ratio pluri-biotech.com|PLUR - Company Assets
- debt and liquidity data:
Debt to Equity Pluri Inc.|PLUR - Long-Term Debt to Equity|Short-Term Debt to Capital Pluri Inc.|PLUR - Company Total Debt Obligations|Debt to Book Capitalization Ratio Pluristem Therapeutics|PLUR - Long-Term Debt Volume|Company Short-Term Debt Pluri|Quick Liquidity pluri-biotech.com
- earnings and valuation multiples indicators:
PLUR - Profit After Tax|Expected Profit Pluri Inc.|PLUR - Price to Earnings Ratio|Projected Price to Earnings Pluri|PLUR - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pluri Inc.|PLUR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Pluri|PLUR - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months pluri-biotech.com|PLUR - Earnings per share increase in current year|Earnings growth forecast for next year Pluri Inc.
- sales volume and revenue information:
PLUR - Company Gross Revenue|Company Projected Revenue Pluri Inc.|PLUR - Market Cap to Revenue Ratio|Forward P/S Multiple Pluri Inc.
Analysis of all company metrics:Pluri Inc.
Manufactured product of Pluri Inc.

The development of 3D cell cultivation technologies for ischemia therapy directly impacts the operational efficiency of Pluri Inc. (PLUR) within the regenerative medicine segment. A quarterly snapshot of EPS growth captures the net profit per share trend, allowing investors to assess the impact of costs on the bottom line and determine the fundamental stability of the stock regardless of temporary market fluctuations.

Competitors of Pluri Inc. (PLUR)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|AARD - Quarterly EPS earnings growth|SGMT: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months BioAge Labs, Inc. (BIOA)|Year-over-year earnings per share growth for the last twelve months Biomea Fusion Inc|Year-over-year earnings per share growth for the last 12 months QNCX (Quince Therapeutics)|Year-over-year net earnings per share growth for the last 12 months GUTS (Fractyl Health)|Year-over-year earnings per share growth rate for the last twelve months VTVT|Agape ATP Corporation - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS